In this online, self-learning activity:
Short bowel syndrome (SBS) is a condition in which a patient exhibits malabsorption-induced diarrhea, dehydration, electrolyte imbalances, and malnutrition due to decreased nutrient absorption that results from extensive surgical resection of the intestine or congenital defects. It is a form of intestinal failure (IF), which is defined as a need for supplementary parenteral or enteral nutrition when intestinal function is insufficient to meet the body’s nutritional requirements. The prevalence of SBS has been estimated to be 3–4 per million patients in the U.S. based on home parenteral nutrition (HPN) data, and in adults undergoing intestinal resection, SBS is estimated to occur in 15% of adult patients, with 75% of patients undergoing a single massive resection.
The following healthcare professionals: gastroenterologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in gastroenterology; and any other healthcare professionals with an interest in or who clinically encounter patients with short bowel syndrome.
This program is supported by an educational grant from Shire.
Release Date: October 07, 2018 -- Expiration Date: October 07, 2020
Faculty: Kalyan Ram Bhamidimarri, MD
- Overview of SBS
- Epidemiology of SBS
- Updates from DDW 2018
By the end of the session the participant will be able to:
ACCME Activity #201226462
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved through content review by ScientiaCME.
Kalyan Ram Bhamidimarri, M.D., MPH, Associate Professor of Clinical Medicine University of Miami/Miami Transplant Institute, has received honorarium from Merck, Gilead, AbbVie, Alexion, Eisai, Intercept, and research grants from Gilead, BMS, Mallinckrodt, Vital Therapies, Ocera Inc, Conatus/ Allergan, and Genfit
Disclosures of Educational Planner: Charles Turck, PharmD, BCPS, BCCCP has no relevant conflicts of interest to disclose.
Disclosures of Peer Reviewer: Ali Rezaie, MD discloses that he has received consulting honorarium from Valeant and Alnylam and owns stock in Gemelli Biotech.
Disclosures of Peer Reviewer: Shirley Paski, MD has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This program is supported by an educational grant from Shire.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Employing biosimilars in the treatment of inflammatory health conditions: How to and should I?
Pediatric Crohn's disease: Therapeutic updates and optimizing treatment
Ulcerative Colitis: Updates from the DDW 2019 Annual Meeting